Amyotrophic lateral sclerosis (ALS) is a relatively common cause of progressive weakness, respiratory failure and death. Although ALS has a low incidence of 1-2 per 100,000/year the cumulative lifetime risk has been shown to be as high as 1 in 338
specifically, a lack of readily accessible patients meeting enrollment criteria, necessitating collaboration across countries and continents to secure sufficient numbers of eligible subjects.
Consortia and infrastructure to facilitate collaborative research into risk factors, genetics, biomarkers, and execution of clinical trials are being developed around the world 3, 4 . Patient registries have been identified as a vital component of the tools required for new therapy development [5] [6] [7] . Patient registries provide real world data that is highly generalizable and has been used to expand indications for medical procedures beyond that of those justified by pivotal clinical trials 8 .
The Northern Ireland motor neuron disease (MND) patient register has demonstrated near complete ascertainment using capture-recapture methodology allowing the registry to provide estimates of incidence, prevalence and geographic distribution 9 .
The utility of such information in Canada is evident given the considerable health care resources required by ALS patients across vast geographic regions and the difficulty in planning clinical trials that should include a representative sample of the Canadian ALS patient population. Existing ALS patient registries have also refined epidemiological estimates of FALS patients in various regions outside of Canada allowing improved feasibility and impact assessments for prospective FALS clinical trials and studies 10 .
Patient registries employ a spectrum of models to register subjects and collect medical data ranging from online selfregistration (often cross referencing with administrative data) to clinic-based registration completed by the attending physician. Importantly, the model employed should meet the needs of the specific patient registry and the function that the registry is aiming to serve.
Although limited epidemiological data on ALS in Canada exists, data on geographic distribution, genetics, potential risk factor exposures, multidisciplinary clinic use, health care utilization and socioeconomic impact remain unavailable. Despite great strides in collaboration by the Canadian ALS Network (CALS) barriers to efficient international level clinical trial planning and recruitment remain due to lack of information technology infrastructure to facilitate study-eligible patient statistics, including geographic distribution relative to study site locations, and a notification system for potentially eligible patients. The Canadian Neuromuscular Disease Registry (CNDR) is a national clinic-based registry of patients with neuromuscular diseases with the goal of facilitating design and execution of clinical research. The CNDR currently collects detailed medical information on patients with Duchenne and myotonic muscular dystrophies and consists of affiliated regional co-investigators and their respective neuromuscular clinics serving as clinical data collection centres. The CNDR is administered centrally through the national office providing logistical and administrative support. Data is entered using an internet portal to transmit data securely from clinical sites to a centralized server. Following extensive discussion between patients, groups providing clinical or support services, clinicians and researchers and through the partnering of the CNDR, CALS and the ALS Society of Canada it was decided to proceed with the creation of an ALS registry in Canada through the addition of detailed ALS medical information collection capabilities to the existing CNDR database. a registry of patients with ALS in Canada and the compatibility of such a registry within the CNDR network. The entire CALS membership including physicians, basic science and clinical researchers, ALS Clinic Directors, and allied health professionals were surveyed. The survey consisted of a webbased questionnaire developed and disseminated through SurveyGizmo (http://www2.surveygizmo.com/; Boulder, CO). The survey asked respondents to describe their: 1. Expertise and affiliation; 2. Local multidisciplinary clinic characteristics if applicable; 3. Approximate number of new and followed ALS patients; 4. Interest or involvement in the CNDR; 5. Interest in participating in the CNDR as an ALS data collection site (ALS Clinic Directors only); 6. Projected benefits of an ALS registry for research and patients in Canada; 7. Projected drawbacks to an ALS registry for research and patients; 8. Desired rank for potential dataset item groupings based on importance to benefit their research and that of their collaborators.
MATERIALS & METHODS
In conjunction with the web-based survey, the CNDR also reviewed: 1. The availability and timing of upcoming clinical trials in ALS; 2. The epidemiologic needs for ALS in Canada; 3. Public health needs in Canada; 4. Availability of funding; 5. Availability of sufficient clinical and research expertise to form an ALS Disease Working Group as required by the CNDR organizational structure.
Expected Case Ascertainment
ALS clinic directors were asked to provide accurate estimates of the number of patients meeting at least El-Escorial criteria for clinically possible ALS in their clinic. Population statistics by province were obtained from the Canadian socioeconomic Highly database from Statistics Canada (CANSIM) 11 . The at-risk population was considered age 25 years and above. The expected number of ALS cases was calculated based upon the previously reported Canadian point prevalence estimate of 6.07 per 100,000 within the Province of Alberta 12 . Expected maximum ascertainment was then calculated by dividing the ALS clinic patient estimates by the expected number of cases based on point prevalence.
Dataset Derivation Meeting. The participants met on April 28th and 29th, 2011 in Toronto, Ontario to derive the ALS dataset. Following introductory remarks, an update on the implementation of the CNDR across Canada, and a tour of the CNDR database, the group began with a facilitated discussion on what the priorities for the Canadian ALS Dataset should be in the context of the international ALS research community and a review of the results of the feasibility survey.
All CNDR datasets are constructed with a minimum dataset approach to help ensure complete, efficient, and accurate data collection within the clinic environment. Accordingly, CNDR dataset items fall within three categories. 1) The Mandatory category contains data items that must be captured at every clinic, and are surveyed nationally for quality control and completion; 2) The Highly Encouraged category contains data items that are of high interest in the research community but due to time and resource constraints may not be possible to collect at every site or clinic visit; 3) The Optional category contains data items that are collected at the specific desire of clinics individually or regionally. Every effort is made to collect all items where possible. The concept for the Mandatory, Highly Encouraged and Optional data categories were based on those from the Translational Research in Europe for the Assessment and Treatment of Neuromuscular Disease (TREAT-NMD) Network Global Registry Toolkit 6 .
In advance of the meeting, the meeting organizers (M. Johnston, L. Korngut) utilized the scored rankings from the webbased feasibility survey dataset ranking to divide dataset item groupings into Mandatory or Highly Encouraged categories. During the survey respondents were also asked to indicate additional groupings they felt were important but were not included in the survey. At the beginning of the meeting on April 29, 2011, Nominal Group Technique (NGT) was employed by the organizers to score and rank these additional items/groupings from the feasibility survey. Nominal Group Technique is a consensus method with an extensive use in the fields of health and medicine. NGT is a "structured meeting" that defines a clear process to obtain consensus from a group of experts or other groups 13 . The data items/groupings with the top three scores were assigned within the Mandatory category with the remainder placed in the Highly Encouraged category. Following this effort, group consensus was obtained with respect to the classification of each data item. To facilitate efficient consensus-based discussion, participants were organized into small groups based on expertise (Demographics/Diagnostics/Genetics; Clinical Features; and Clinical Trials). Each group consisted of four members and was responsible for determining the data field inputs and parameters within each Mandatory category. Each group was required to achieve consensus on the individual items discussed and any items for which consensus could not be achieved were discussed with all of the participants in a larger group session. If large group consensus could not be reached, then the NGT would be employed to re-rank the controversial items. The entire process was then repeated to achieve consensus on data items within the Highly Encouraged and Optional category.
Following the Dataset Derivation Meeting a draft data collection form was sent to the meeting attendees to ensure all data fields and parameters had been captured accurately. Subsequently, the final dataset was circulated a second time to all meeting participants, the CNDR Advisory Committee and the ALS Society of Canada for approval in accordance with CNDR procedure.
RESULTS

ALS Feasibility
Survey. The ALS web questionnaire was sent to the entire CALS network that included 59 clinicians, researchers and allied health professionals. Twenty-four respondents completed the questionnaire (41%). Respondents identified themselves as ALS clinic directors (37.5%), basic scientists (4.2%), clinicians (29.17%), and clinical researchers (29.2%). Eleven multidisciplinary ALS clinic directors completed the questionnaire. Seventy five percent of respondents indicated that their patients were seen in a dedicated ALS clinic.
Respondents ranked possible dataset item groupings according to perceived importance to their research and that of their collaborators. Table 1 lists the top nine groupings by average rank (low score = high importance).
Sixteen professionals responded that they were interested in participating in the ALS Disease Working Group that would oversee the development and maintenance of the ALS dataset, provide peer review for data release inquiries, and provide oversight for scientific integrity of the ALS component of the CNDR. Sixteen experts responded with interest in participating in the Dataset Derivation meeting with some overlap with those demonstrating interest in the disease working group. The feasibility web questionnaire identified sufficient interest from ALS clinicians and researchers in participating in the proposed registry to justify proceeding further. The feasibility survey findings were reviewed by representatives from CALS, the ALS Society of Canada and the CNDR. Considerations included upcoming and ongoing clinical trials and studies in ALS, gaps in understanding of the epidemiology of ALS in Canada and ability of the proposed registry to generate data to advocate for public health needs of the ALS population. It was unanimously agreed to proceed with the development of a Canadian ALS dataset.
LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES
Expected Case Ascertainment. Expected case ascertainment was calculated by province and was found to be higher than expected based on the available population-based point prevalence estimate. Calculations are summarized in Table 2 .
ALS Dataset Development. In April 2011, twelve experts from neurology, physiatry and clinical genetics attended the Dataset Derivation meeting in Toronto, Ontario. In advance of the meeting, based on the average score from the feasibility webbased questionnaire the nine ranked data groupings (Table 3) were divided into Mandatory and Highly Encouraged items.
Meeting attendees were asked to score additional item groupings captured during the web-based feasibility questionnaire based on a relevance scoring matrix ( Table 4 ). The aggregated scores were used to rank the item groupings with the top five being assigned to the Mandatory category for further discussion (Table 5) .
Mandatory Items Discussion. For the items in the Mandatory category, three small groups each with four members were formed. Consensus was achieved on all data fields and parameters at the small group level. The final dataset items and parameters produced by each group appear in Table 6 .
Highly Encouraged Items Discussion. For the items in the Highly Encouraged category, four small groups each with three members were formed. Large group discussion about palliative care, cognitive abilities, and access to healthcare services occurred. The final dataset items and parameters produced appear in Table 7 .
In total the dataset comprises 103 discrete fields, 49 of these are in the Mandatory category. Data will be collected at CNDR clinical sites employing both a physician data collection form (medical data) and a patient data collection form (mainly sociodemographic data) to increase efficiency with the larger dataset.
DISCUSSION
The CNDR aims to facilitate clinical research into neuromuscular diseases in Canada. Data collected by patient registries is particularly useful as it is highly generalizable to the patient population studied. Patient registry findings are most generalizable when they are demonstrated to be populationbased. The initial aim of the ALS component of the CNDR is to demonstrate population-based level case ascertainment in multiple provinces and ultimately on a national level. To assess the feasibility of eventual complete or near complete ascertainment of ALS cases we calculated the expected maximum case ascertainment based upon ALS clinic estimates of number of cases compared to calculations of expected cases based on previously reported point prevalence demonstrated higher than expected ascertainment. The estimated actual number of ALS cases within ALS clinics participating in this study exceeded the expected cases derived from a populationbased point prevalence estimate. Despite the lack of clinics in certain regions (e.g. Northern Ontario, Prince Edward Island and Newfoundland) the overall number of actual ALS cases within the participating 14 clinics was 123% of the expected number of cases in Canada. The higher than expected number of actual cases further supports the usefulness of a national patient registry to delineate the epidemiology of ALS in Canada and assess discrepancies between the expected and actual burdens of ALS in Canada. There are possible explanations that must be considered including overestimation of existing ALS cases in ALS clinics but we feel that this is unlikely given the consistent use of clinical databases and visit scheduling software in determining actual case numbers for this study. We also feel it is unlikely that ALS patients are being seen regularly in multiple clinics based on referral patterns and communication between clinics for patients outside of specific clinic catchment areas. Future research on the epidemiology of ALS will be facilitated by this registry once implemented.
The derivation of the ALS dataset from feasibility study to finalized dataset took approximately eight months (November 2010 to July 2011). The dataset was derived both with strong investigator and clinician support and also a robust methodology to minimize bias. The inclusion of a breadth of professionals including clinicians, researchers and allied health professionals in the feasibility study resulted in broad dataset items that reflect the needs of the Canadian ALS clinical and research communities. The viability of each dataset item will be closely monitored by the CNDR ALS Disease Working Group upon initiation of data collection and the dataset will be accordingly revised to remove any items collected with insufficient frequency. Software design of the data collection module for the CNDR will begin in January 2012 and data collection will begin in CNDR clinics nationally in mid-2012. Building this long sought-after resource is a significant step forward for the Canadian ALS patient and research communities.
